| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
66,921,000 |
| Market
Cap: |
2.83(B) |
| Last
Volume: |
1,212,774 |
Avg
Vol: |
1,000,279 |
| 52
Week Range: |
$38.26 - $93.23 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile QuidelOrtho is engaged in the development, manufacturing and marketing of diagnostic testing solutions. Co. provides diagnostic testing solutions under various brand names, including, among others, the following: Quidel®, QuickVue®, QuickVue+®, Sofia®, Triage®, Solana®, Virena®, MicroVue™, Lyra®, FreshCells™, D3®, FastPoint®, ReadyCells®, Super E-Mix™, InflammaDry®, AdenoPlus®, ELVIRA®, ELVIS® and Thyretain®. Co.'s diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions and specialized diagnostic solutions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Steward Randall J |
Chief Financial Officer |
• – – |
2020-08-03 |
4 |
S |
$286.31 |
$6,060,126 |
D/D |
(21,166) |
2,848 |
|
30% |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2020-08-03 |
4 |
OE |
$15.40 |
$390,657 |
D/D |
21,166 |
24,014 |
|
- |
|
| Michael Edward L |
Director |
– • – |
2020-08-03 |
4 |
B |
$288.12 |
$1,008,404 |
D/D |
3,500 |
6,434 |
2.39 |
-30% |
|
| Kroll Werner |
SVP, R&D |
• – – |
2020-08-03 |
4 |
S |
$287.48 |
$595,650 |
D/D |
(2,072) |
4,599 |
|
30% |
|
| Buechler Kenneth F |
Director |
– • – |
2020-08-03 |
4 |
S |
$289.22 |
$2,255,946 |
D/D |
(7,800) |
59,824 |
|
30% |
|
| Buechler Kenneth F |
Director |
– • – |
2020-08-03 |
4 |
OE |
$14.43 |
$112,554 |
D/D |
7,800 |
67,624 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2020-06-11 |
4 |
B |
$160.33 |
$801,670 |
D/D |
5,000 |
445,823 |
2.81 |
55% |
|
| Kroll Werner |
SVP, R&D |
• – – |
2020-05-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,304) |
6,671 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2020-05-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,376 |
8,975 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2020-05-22 |
4 |
S |
$174.44 |
$11,888,149 |
D/D |
(68,152) |
4,599 |
|
-39% |
|
| Kroll Werner |
SVP, R&D |
• – – |
2020-05-22 |
4 |
OE |
$15.40 |
$1,394,422 |
D/D |
68,152 |
72,751 |
|
- |
|
| Bujarski Robert Joseph |
SVP, NA Comm Ops & Gen Counsel |
• – – |
2020-05-20 |
4 |
S |
$189.41 |
$3,788,282 |
D/D |
(20,000) |
13,383 |
|
-21% |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic UnitOffi |
• – – |
2020-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,390 |
|
11% |
|
| Abney Michael Donald Jr. |
SVP - Distribution |
• – – |
2020-05-18 |
4 |
S |
$198.12 |
$3,169,387 |
D/D |
(15,970) |
6,634 |
|
-11% |
|
| Abney Michael Donald Jr. |
SVP - Distribution |
• – – |
2020-05-18 |
4 |
OE |
$15.40 |
$286,675 |
D/D |
15,970 |
13,806 |
|
- |
|
| Borkar Ratan S |
SVP, Intl Comm Operations |
• – – |
2020-05-18 |
4 |
S |
$192.53 |
$5,459,113 |
D/D |
(28,312) |
524 |
|
-11% |
|
| Borkar Ratan S |
SVP, Intl Comm Operations |
• – – |
2020-05-18 |
4 |
OE |
$15.40 |
$520,699 |
D/D |
16,332 |
27,171 |
|
- |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2020-05-18 |
4 |
S |
$185.35 |
$3,707,040 |
D/D |
(20,000) |
2,848 |
|
-11% |
|
| Slacik Charles P |
Director |
– • – |
2020-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
549 |
11,352 |
|
- |
|
| Buechler Kenneth F |
Director |
– • – |
2020-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,842 |
59,824 |
|
- |
|
| Slacik Charles P |
Director |
– • – |
2020-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,100 |
10,803 |
|
- |
|
| Buechler Kenneth F |
Director |
– • – |
2020-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,100 |
57,982 |
|
- |
|
| Michael Edward L |
Director |
– • – |
2020-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,100 |
2,934 |
|
- |
|
| Strobeck Matthew |
Director |
– • – |
2020-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,100 |
7,399 |
|
- |
|
| Widder Kenneth J |
Director |
– • – |
2020-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,100 |
14,416 |
|
- |
|
799 Records found
|
|
Page 9 of 32 |
|
|
2.54 (6.4%) 
